HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
Author
Abstract
Suggested Citation
DOI: 10.1038/s41467-024-46558-4
Download full text from publisher
References listed on IDEAS
- J. Joseph Melenhorst & Gregory M. Chen & Meng Wang & David L. Porter & Changya Chen & McKensie A. Collins & Peng Gao & Shovik Bandyopadhyay & Hongxing Sun & Ziran Zhao & Stefan Lundh & Iulian Pruteanu, 2022. "Decade-long leukaemia remissions with persistence of CD4+ CAR T cells," Nature, Nature, vol. 602(7897), pages 503-509, February.
- Elise Alspach & Danielle M. Lussier & Alexander P. Miceli & Ilya Kizhvatov & Michel DuPage & Adrienne M. Luoma & Wei Meng & Cheryl F. Lichti & Ekaterina Esaulova & Anthony N. Vomund & Daniele Runci & , 2019. "MHC-II neoantigens shape tumour immunity and response to immunotherapy," Nature, Nature, vol. 574(7780), pages 696-701, October.
- Douglas B. Johnson & Monica V. Estrada & Roberto Salgado & Violeta Sanchez & Deon B. Doxie & Susan R. Opalenik & Anna E. Vilgelm & Emily Feld & Adam S. Johnson & Allison R. Greenplate & Melinda E. San, 2016. "Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy," Nature Communications, Nature, vol. 7(1), pages 1-10, April.
- J. Joseph Melenhorst & Gregory M. Chen & Meng Wang & David L. Porter & Changya Chen & McKensie A. Collins & Peng Gao & Shovik Bandyopadhyay & Hongxing Sun & Ziran Zhao & Stefan Lundh & Iulian Pruteanu, 2022. "Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells," Nature, Nature, vol. 612(7941), pages 22-22, December.
- Caroline Robert, 2020. "A decade of immune-checkpoint inhibitors in cancer therapy," Nature Communications, Nature, vol. 11(1), pages 1-3, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Ariel Isser & Aliyah B. Silver & Hawley C. Pruitt & Michal Mass & Emma H. Elias & Gohta Aihara & Si-Sim Kang & Niklas Bachmann & Ying-Yu Chen & Elissa K. Leonard & Joan G. Bieler & Worarat Chaisawangw, 2022. "Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
- Raymond Hall Yip Louie & Curtis Cai & Jerome Samir & Mandeep Singh & Ira W. Deveson & James M. Ferguson & Timothy G. Amos & Helen Marie McGuire & Kavitha Gowrishankar & Thiruni Adikari & Robert Balder, 2023. "CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Tomás A. Martins & Deniz Kaymak & Nazanin Tatari & Fiona Gerster & Sabrina Hogan & Marie-Françoise Ritz & Valerio Sabatino & Ronja Wieboldt & Ewelina M. Bartoszek & Marta McDaid & Alexandra Gerber & A, 2024. "Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker," Nature Communications, Nature, vol. 15(1), pages 1-25, December.
- Ugur Uslu & Lijun Sun & Sofia Castelli & Amanda V. Finck & Charles-Antoine Assenmacher & Regina M. Young & Zhijian J. Chen & Carl H. June, 2024. "The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
- Elisa Landoni & Mark G. Woodcock & Gabriel Barragan & Gabriele Casirati & Vincenzo Cinella & Simone Stucchi & Leah M. Flick & Tracy A. Withers & Hanna Hudson & Giulia Casorati & Paolo Dellabona & Piet, 2024. "IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
- Dan Li & Ruixue Wang & Tianyuzhou Liang & Hua Ren & Chaelee Park & Chin-Hsien Tai & Weiming Ni & Jing Zhou & Sean Mackay & Elijah Edmondson & Javed Khan & Brad St Croix & Mitchell Ho, 2023. "Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
- Qianqian Ming & Daniel Antfolk & David A. Price & Anna Manturova & Elliot Medina & Srishti Singh & Charlotte Mason & Timothy H. Tran & Keiran S. M. Smalley & Daisy W. Leung & Vincent C. Luca, 2024. "Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
- Teresa Maria Rosaria Noviello & Anna Maria Giacomo & Francesca Pia Caruso & Alessia Covre & Roberta Mortarini & Giovanni Scala & Maria Claudia Costa & Sandra Coral & Wolf H. Fridman & Catherine Sautès, 2023. "Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Ulrich Blache & Georg Popp & Anna Dünkel & Ulrike Koehl & Stephan Fricke, 2022. "Potential solutions for manufacture of CAR T cells in cancer immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
- Yue Wang & Shi-Kun Zhou & Yan Wang & Zi-Dong Lu & Yue Zhang & Cong-Fei Xu & Jun Wang, 2023. "Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Avishai Maliah & Nadine Santana-Magal & Shivang Parikh & Sagi Gordon & Keren Reshef & Yuval Sade & Aseel Khateeb & Alon Richter & Amit Gutwillig & Roma Parikh & Tamar Golan & Matan Krissi & Manho Na &, 2024. "Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
- Dhivya Sridaran & Surbhi Chouhan & Kiran Mahajan & Arun Renganathan & Cody Weimholt & Shambhavi Bhagwat & Melissa Reimers & Eric H. Kim & Manish K. Thakur & Muhammad A. Saeed & Russell K. Pachynski & , 2022. "Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance," Nature Communications, Nature, vol. 13(1), pages 1-21, December.
- Laura Y. Zhou & Fei Zou & Wei Sun, 2023. "Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA‐I proteins," Biometrics, The International Biometric Society, vol. 79(3), pages 2664-2676, September.
- Zhigui Zuo & Hao Yin & Yu Zhang & Congying Xie & Qinyang Wang, 2023. "A cytotoxic T cell inspired oncolytic nanosystem promotes lytic cell death by lipid peroxidation and elicits antitumor immune responses," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Georges Bedran & Daniel A. Polasky & Yi Hsiao & Fengchao Yu & Felipe Veiga Leprevost & Javier A. Alfaro & Marcin Cieslik & Alexey I. Nesvizhskii, 2023. "Unraveling the glycosylated immunopeptidome with HLA-Glyco," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
- Samuel Rivero-Hinojosa & Melanie Grant & Aswini Panigrahi & Huizhen Zhang & Veronika Caisova & Catherine M. Bollard & Brian R. Rood, 2021. "Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
- Jens Bauer & Natalie Köhler & Yacine Maringer & Philip Bucher & Tatjana Bilich & Melissa Zwick & Severin Dicks & Annika Nelde & Marissa Dubbelaar & Jonas Scheid & Marcel Wacker & Jonas S. Heitmann & S, 2022. "The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
- Su Yin Lim & Elena Shklovskaya & Jenny H. Lee & Bernadette Pedersen & Ashleigh Stewart & Zizhen Ming & Mal Irvine & Brindha Shivalingam & Robyn P. M. Saw & Alexander M. Menzies & Matteo S. Carlino & R, 2023. "The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Denise Lau & Sonal Khare & Michelle M. Stein & Prerna Jain & Yinjie Gao & Aicha BenTaieb & Tim A. Rand & Ameen A. Salahudeen & Aly A. Khan, 2022. "Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
- John P. Finnigan & Jenna H. Newman & Yury Patskovsky & Larysa Patskovska & Andrew S. Ishizuka & Geoffrey M. Lynn & Robert A. Seder & Michelle Krogsgaard & Nina Bhardwaj, 2024. "Structural basis for self-discrimination by neoantigen-specific TCRs," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46558-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.